Oral Minoxidil and Atorvastatin Interaction: Safety, Risks, and Monitoring

Is an interaction listed in either label?

Neither label names the other drug as an interacting medicine.

The oral minoxidil tablet label has a one-line drug interaction section that points to a single drug, guanethidine, which can cause profound orthostatic effects when given with minoxidil [1]. The Lipitor (atorvastatin) label's interaction tables cover cyclosporine, gemfibrozil, several antivirals, azole antifungals and macrolide antibiotics, lipid-modifying doses of niacin, other fibrates, colchicine, grapefruit juice, rifampin, oral contraceptives and digoxin; minoxidil is not among them [2].

A missing listing is not the same as a tested result. It does not show that the pair has been studied together.

How each drug is handled in the body

Atorvastatin is a substrate of CYP3A4 and of the transporters OATP1B1/1B3, P-gp and BCRP, and the label warns that inhibiting those pathways can raise atorvastatin exposure and the risk of myopathy and rhabdomyolysis [2]. In label studies, clarithromycin 500 mg twice daily raised atorvastatin 80 mg exposure 4.54-fold and itraconazole 200 mg daily raised a single 40 mg dose 3.32-fold; the Lipitor label says not to exceed 20 mg daily with either drug [2]. Atorvastatin's half-life is about 14 hours, and its circulating inhibitory activity lasts 20 to 30 hours [2].

Oral minoxidil runs on a different system. It is at least 90% absorbed, peaks in plasma within the first hour, has an average half-life of 4.2 hours, and about 90% is metabolized, mainly by glucuronide conjugation, with no CYP enzyme named in the label [1]. The blood-pressure effect lasts far longer than the plasma level would suggest, about 75 hours [1]. Minoxidil's blood-pressure-lowering action is attributed to its sulphated metabolite acting as a potassium-channel (KATP) opener [5].

The minoxidil label's description of metabolism does not settle whether the combination changes atorvastatin levels [1].

What low-dose oral minoxidil does to blood pressure and heart rate

Hair-loss doses are far below antihypertensive doses. Minoxidil tablets are started at 5 mg daily for hypertension and usually run 10 to 40 mg daily [1]. Trials of oral minoxidil for hair loss have used 1 mg daily and 5 mg daily, and a meta-analysis defined low dose as 5 mg per day or less [6][7][3].

A pooled analysis found the mean change in systolic pressure was -0.13 mm Hg (95% CI -2.67 to 2.41) and in diastolic pressure -1.25 mm Hg (95% CI -3.21 to 0.71), with heart rate up 2.67 beats per minute (95% CI 0.34 to 5.01) [3]. Hypotensive symptoms were reported in 119 patients (5.0%), though no hypotensive episodes occurred; the included studies were uncontrolled [3].

In a 1,404-patient safety cohort, lightheadedness occurred in 1.7%, tachycardia in 0.9%, fluid retention in 1.3%, headache in 0.4% and periorbital edema in 0.3%, and 1.2% stopped treatment because of systemic effects [4]. A dose-response analysis of six studies found each extra 1 mg per day was associated with a 4.8% higher risk of cardiovascular adverse events at six months, which is an observational association rather than proof of cause [8].

Fluid retention and edema

The minoxidil label treats salt and water retention as the main hazard of the drug at antihypertensive doses. It says the tablets must usually be given with a diuretic, that a loop diuretic is almost always required, and that reversible edema still developed in about 10% of non-dialysis patients treated this way; temporary edema appeared in 7% of patients who had none at the start [1]. At hair-loss doses the reported rate is much lower, 1.3% in the 1,404-patient cohort [4].

For its approved hypertension use, the oral minoxidil label requires close supervision and usually concomitant treatment with a diuretic and a beta blocker [1]. Low-dose hair-loss studies still reported fluid retention and tachycardia [4].

Liver enzymes

The atorvastatin label reports persistent transaminase elevations above 3 times the upper limit of normal in about 0.7% of trial patients overall, with a clear dose gradient: 0.2% at 10 mg, 0.2% at 20 mg, 0.6% at 40 mg and 2.3% at 80 mg [2]. The label says to consider liver enzyme testing before starting and when clinically indicated afterwards, and lists acute liver failure or decompensated cirrhosis as a contraindication [2].

Oral minoxidil's label lists alkaline phosphatase increases of varying size without other evidence of liver or bone abnormality, and an average 6% rise in serum creatinine that later declined to pretreatment levels [1].

Atorvastatin's own cautions

Atorvastatin carries no boxed warning, but the label highlights myopathy and rhabdomyolysis, with risk factors that include age 65 or older, uncontrolled hypothyroidism, renal impairment, interacting drugs and higher doses; the label says patients should promptly report unexplained muscle pain, tenderness or weakness, especially with malaise or fever [2]. Rare immune-mediated necrotizing myopathy and rises in HbA1c and fasting glucose are also listed [2]. The label advises avoiding large quantities of grapefruit juice, more than 1.2 liters daily; in a label study, 240 mL daily raised the exposure to a single 40 mg dose 1.37-fold [2].

Timing and grapefruit

The Lipitor label permits once-daily dosing at any time of day, with or without food [2]. The minoxidil label's dosing instructions concern blood-pressure titration, with adjustments no more often than every 3 days [1].

The grapefruit caution belongs to atorvastatin alone [2]; the minoxidil tablet label's interaction section does not mention grapefruit juice [1].

Who should not take them

Minoxidil tablets are contraindicated in pheochromocytoma, because the drug may stimulate catecholamine release from the tumor, and in anyone with hypersensitivity to a component [1]. Atorvastatin is contraindicated in acute liver failure or decompensated cirrhosis and in hypersensitivity to atorvastatin or an excipient [2]. Neither contraindication involves the other drug.